Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ALDX
Stock Latest News
Ratings
Maintaining Hold on Aldeyra as FDA CRL Clouds Reproxalap’s Dry Eye Path and Lowers Approval Odds
9d ago
ALDX
Premium
The Fly
Aldeyra downgraded to Neutral from Buy at H.C. Wainwright
9d ago
ALDX
Premium
Market News
Morning News Wrap-Up 3/17/26: Today’s Biggest Stock Market Stories!
10d ago
MA
MU
Premium
The Fly
FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy
10d ago
ALDX
Premium
Market News
How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?
10d ago
ALDX
Premium
Company Announcements
FDA Issues Second Complete Response Letter for Reproxalap
10d ago
8K
ALDX
Premium
The Fly
Aldeyra options imply 10.9% move in share price post-earnings
22d ago
ALDX
Premium
Company Announcements
Aldeyra Therapeutics Announces Chief Development Officer Resignation
3M ago
8K
ALDX
Premium
Ratings
Aldeyra Therapeutics: Buy Rating Affirmed Amid Promising Drug Development and Robust Investment Potential
3M ago
ALDX
Premium
The Fly
Midday Fly By: Ford takes $19.5B EV writedown, Apple expanding iPhone lineup
3M ago
F
F
Premium
Ratings
Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside
3M ago
ALDX
Premium
The Fly
Unusually active option classes on open December 16th
3M ago
F
BP
Premium
Company Announcements
Aldeyra Therapeutics Faces FDA PDUFA Date Extension
3M ago
8K
ALDX
Premium
The Fly
Aldeyra announces PDUFA extension for Reproxalap
3M ago
ALDX
Premium
Company Announcements
Aldeyra Therapeutics Completes Promising Phase 2 Trial for Alcohol-Associated Hepatitis
3M ago
ALDX
Premium
Ratings
Aldeyra Therapeutics: Promising Advancements and Strategic Positioning Drive Buy Rating
4M ago
ALDX
Premium
Ratings
Promising Developments and Regulatory Progress Drive Buy Rating for Aldeyra Therapeutics
4M ago
ALDX
Premium
The Fly
Aldeyra expands RASP platform
4M ago
ALDX
Premium
Company Announcements
Aldeyra Therapeutics Expands RASP Platform in 2025 Webcast
4M ago
8K
ALDX
Premium
The Fly
Aldeyra ADX-629 achieves statistically significant improvement in liver function
5M ago
ALDX
Premium
Company Announcements
Aldeyra Therapeutics Reports Positive Phase 2 Trial Results
5M ago
8K
ALDX
Premium
Company Announcements
Aldeyra Therapeutics Advances with Promising Hepatitis Treatment Trial
5M ago
ALDX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
